VOLPINI, Rosaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.532
EU - Europa 5.977
AS - Asia 2.751
SA - Sud America 100
Continente sconosciuto - Info sul continente non disponibili 49
AF - Africa 12
OC - Oceania 7
Totale 23.428
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.069
CN - Cina 1.977
PL - Polonia 1.483
IT - Italia 1.139
DE - Germania 808
UA - Ucraina 529
SE - Svezia 490
CA - Canada 457
GB - Regno Unito 441
SG - Singapore 405
FR - Francia 265
FI - Finlandia 263
RU - Federazione Russa 257
TR - Turchia 178
IE - Irlanda 127
BR - Brasile 77
EU - Europa 49
BE - Belgio 44
VN - Vietnam 40
CZ - Repubblica Ceca 33
IN - India 30
IR - Iran 25
KR - Corea 22
NL - Olanda 21
HK - Hong Kong 19
RO - Romania 17
ES - Italia 12
AT - Austria 11
JP - Giappone 11
DK - Danimarca 7
CL - Cile 6
AU - Australia 5
EC - Ecuador 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
GR - Grecia 4
JO - Giordania 4
LB - Libano 4
TW - Taiwan 4
AL - Albania 3
AR - Argentina 3
AZ - Azerbaigian 3
IL - Israele 3
IQ - Iraq 3
MX - Messico 3
RS - Serbia 3
TH - Thailandia 3
VE - Venezuela 3
ZA - Sudafrica 3
BO - Bolivia 2
CO - Colombia 2
DZ - Algeria 2
GT - Guatemala 2
KH - Cambogia 2
MA - Marocco 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PE - Perù 2
PH - Filippine 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
AM - Armenia 1
BD - Bangladesh 1
BG - Bulgaria 1
BT - Bhutan 1
BY - Bielorussia 1
CM - Camerun 1
CR - Costa Rica 1
EE - Estonia 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
KE - Kenya 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MT - Malta 1
NG - Nigeria 1
QA - Qatar 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
UZ - Uzbekistan 1
Totale 23.428
Salva come PNG Salva come JPEG
Città #
Fairfield 1.762
Woodbridge 1.493
Jacksonville 1.322
Warsaw 1.294
Chandler 1.053
Houston 1.045
Ashburn 918
Seattle 768
Wilmington 751
Ann Arbor 647
Cambridge 605
Boardman 562
Nanjing 460
Toronto 322
Singapore 254
Camerino 219
San Mateo 199
Dearborn 188
Kraków 185
Lawrence 180
Princeton 180
Beijing 169
Düsseldorf 164
Istanbul 154
Columbus 152
Ogden 146
Lachine 128
Dublin 126
Nanchang 123
Helsinki 109
London 104
Moscow 94
Shanghai 94
Shenyang 87
San Diego 84
New York 83
Tianjin 80
Guangzhou 76
Milan 76
Kunming 74
Hebei 62
Jiaxing 55
Los Angeles 55
Brussels 44
Changsha 39
Chicago 39
Redwood City 39
Jinan 38
Ningbo 38
Wuhan 38
Centro 36
Dong Ket 35
Munich 33
Hangzhou 32
Venezia 31
Zhengzhou 30
Verona 29
Philadelphia 28
Hefei 27
Brno 25
Falls Church 25
Norwalk 25
Orange 24
Jinhua 22
Kocaeli 22
Nürnberg 22
Detroit 21
Frankfurt am Main 21
Bremen 20
Perugia 19
Taizhou 19
Lanzhou 18
Leawood 17
Washington 17
Auburn Hills 16
Rome 16
San Francisco 15
Tappahannock 15
Venice 15
Ardabil 14
Changchun 14
Yiwu 14
Council Bluffs 12
Scafati 12
Buffalo 11
Shenzhen 11
Andover 10
Hounslow 10
Phoenix 10
Acton 9
Ancona 9
Bologna 9
Indiana 9
Kilburn 9
Osimo 9
Pescara 9
São Paulo 9
Meppel 8
Nantong 8
New Bedfont 8
Totale 17.866
Salva come PNG Salva come JPEG
Nome #
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 333
Overview on Radiolabel-Free in Vitro Assays for GPCRs 319
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 290
1,2,4-Triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure–affinity relationships and molecular modeling studies 285
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A2A Receptor Subtype 284
Pharmacological characterization of the GPR17 receptor dual profile 274
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 269
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 261
The G Protein-Coupled Receptor GPR17: Overview and Update 254
Medicinal chemistry and pharmacology of A2B adenosine receptors 245
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease 236
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-ones 224
Neuroprotective potential of adenosine A1 receptor partial agonists in experimental models of cerebral ischemia 214
Adenine based acyclic-nucleotides as novel P2X3 receptor ligands 212
8-(2-Furyl)adenine derivatives as A2A adenosine receptor ligands 209
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 206
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 198
Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists 191
GPR17 receptor modulators and their therapeutic implications: review of recent patents 189
Human cytidine deaminase: understanding the catalytic mechanism 184
Neuropeptide S Receptor: recent updates on non-peptide antagonist discovery 180
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 179
Purinergic P2X receptors: Structural models and analysis of ligand-target interaction 178
Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs 173
Antioxidant-conjugated 1,2,4-Triazolo[4,3-a]pyrazin-3-one Derivatives: Highly Potent and Selective Human A2A Adenosine Receptor Antagonists Possessing Protective Efficacy in Neuropathic Pain 172
Purine and deazapurine nucleosides: synthetic approaches, molecular modeling and biological activity 169
2-Aralkynyl and 2-Heteroalkynyl derivatives of Adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists 169
Human placenta cytidine deaminase: a zinc metalloprotein 168
Levels of polychlorinated biphenyls in fish and shellfish from the Adriatic Sea 168
3'-Deoxyribofuranose derivatives of 1-deaza and 3-deaza adenosine and their activity as adenosine deaminase inhibitors 166
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity 164
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 163
New sensible method to quantize the intestinal absorption of receptor ligands 163
“Third Joint Italian-German Purine Club Meeting - Purinergic Receptors: New Frontiers for Novel Therapies” 161
Determination of ink photoinitiators in packaged beverages by gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry 161
CX3CL1-induced modulation at CA1 synapses reveals multiple mechanisms of EPSC modulation involving adenosine receptor subtypes. 160
Isoenzymatic forms of human cytidine deaminase 159
9-ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities 159
2-Alkynyl derivatives of adenosine and adenosine-5'-N-ethyluronamide as selective agonists at A2 adenosine receptors 158
Novel 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives as potent human adenosine A1 and A2A receptor antagonists. Evaluation of their protective effect against β-amyloid-induced neurotoxicity in SH-SY5Y cells 158
Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases 158
Comparison and optimization of transient transfection methods at human astrocytoma cell line 1321N1 157
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family 157
2-Substituted N-ethylcarboxamidoadenosine derivatives as high affinity agonists at human A(3) adenosine receptors 157
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 156
Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1 156
Biomarkers mapping of neuropathic pain in a nerve chronic constriction injury mice model 155
Adenosine deaminase: Functional implications and different classes of inhibitors 154
Evidence for the existence of a specific G protein-coupled receptor activated by guanosine 154
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 153
Antiviral properties of deazaadenine nucleoside derivatives 153
Molecular modeling studies on the human neuropeptide S receptor and its antagonists. 152
Innovative functional cAMP assay for studying G protein-coupled receptors: application to the pharmacological characterization of GPR17 152
Adenosine deaminase inhibitors: synthesis and structure-activity relationships of 2-hydroxy-3-nonyl derivatives of azoles 151
Molecular modeling study on potent and selective adenosine A3 receptor agonists. 151
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors 151
Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor. 150
Identification of alpha(1)-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens 149
Synthesis and receptor affinity of polysubstituted adenosines 149
A(2A) adenosine receptor agonists reduce both high-palatability and low-palatability food intake in female rats 149
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 149
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor 148
The importance of alkynyl chain presence for the activity of adenine nucleosides/nucleotides on purinergic receptors 147
Exploring the 7-oxo-thiazolo[5,4-d]pyrimidine core for the design of new human adenosine A3 receptor antagonists. Synthesis, molecular modeling studies and pharmacological evaluation 147
Ring opening reactions: synthesis of AICAR analogs as potential antimetabolite agents 146
GPCRs as therapeutic targets: a view on adenosine receptors structure and functions, and molecular modeling support 145
Chemical and pharmacological profile of selective adenosine receptor agonists 145
Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity 144
Adenosine A(2A) receptor antagonists: new 8-substituted 9-ethyladenines as tools for in vivo rat models of Parkinson's disease 143
Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor 143
Synthesis and adenosine deaminase inhibitory activity of 3’-deoxy-1-deazaadenosines 143
Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists 143
Unexpected synthesis of acyclic adenine nucleosides 142
Diazepinone nucleosides as inhibitors of cytidine deaminase 142
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: Insight into the receptor activation switch 142
Potent and selective ligands for adenosine binding sites 142
Coupling of 2,6-disubstituted purines to ribose-modified sugars 141
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A1/A2B Partial Agonists 141
Adenosine receptor modeling: what does the A2A crystal structure tell us? 140
2-Alkynyl derivatives of Adenosine-5'-N-ethyluronamide (NECA): selective A2 adenosine receptor agonists with potent inhibitory activity on Platelet aggregation 138
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A(2A) and A(2B) receptors ligands 138
New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile 135
Coupling of 2,6-dichloropurine and 2,6-dichlorodeazapurines with ribose and ribose modified sugars 134
Structure-activity relationships of adenosine deaminase inhibitors 134
N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A1 adenosine receptor 133
A(2A) Adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists 132
Synthesis and stability studies of 2 ',3 ',5 '-tri-O-acetyl-2-amino(-N-6-cyclopentyl)-1-deazaadenosines 131
Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists 131
Synthesis and adenosine receptor affinity and potency of 8-alkynyl derivatives of adenosine 131
Modulation of apoptosis in human lymphocytes by adenosine analogues 128
Evidence for the functional expression and pharmacological characterization of adenine receptors in native cells and tissues 128
Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists 125
New substituted 9-alkylpurines as adenosine receptor ligands 125
Effects of 5 '-phosphate derivatives of 2-hexynyl adenosine and 2-phenylethynyl adenosine on responses of human platelets mediated by P2Y receptors 124
2- And 8- alkynyladenosines: conformational studies and docking to human adenosine A(3) receptor can explain their different biological behavior 123
Well water in central Italy: Analysis of herbicide residues as potential pollutants of untreated crops 123
Characterization of potent ligands at human recombinant adenosine receptors 123
Antiviral activity of purine nucleoside analogs against bovine herpesvirus (BHV-1) and maedi visna virus (MVV) 123
Human adenosine A3 receptor as selective target of new 2-aralkynyl-N6-methyl-MECA derivatives 122
2-substituted 5 '-N-methylcarboxamidoadenosine (MECA) derivatives as A(3) adenosine receptor ligands 120
Totale 16.703
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.007
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.007
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.955 0 0 0 0 0 0 361 457 323 312 179 323
2020/20214.181 166 325 237 316 266 463 731 113 364 210 602 388
2021/20222.229 234 534 55 91 122 119 102 167 170 235 157 243
2022/20232.525 256 144 76 420 277 361 11 154 461 134 165 66
2023/20241.883 265 100 110 76 87 173 87 104 222 62 49 548
2024/20251.795 231 140 527 295 200 361 41 0 0 0 0 0
Totale 23.870